SCHEMBL4279489

SCHEMBL4279489

CC(CCC(O)[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C)CC(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 8/20 0.68
▸ NR1H4 Q96RI1 4/20 0.68
▸ SLC10A2 Q12908 2/20 0.68
▸ PDE3A Q14432 2/20 0.68
▸ TBXA2R P21731 1/20 0.68
▸ MAPT P10636 3/20 0.60
▸ MAPK1 P28482 3/20 0.60
▸ USP2 O75604 2/20 0.60
▸ LMNA P02545 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ CASP7 P55210 3/20 0.54
▸ TP53 P04637 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ BLM P54132 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ MDM4 O15151 1/20 0.54
▸ HSPD1 P10809 1/20 0.54
▸ VDR P11473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4279494 1.00 GPBAR1 (0.68) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL2293894 0.85 GPBAR1 (0.69) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL15145513 0.85 GPBAR1 (0.81) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL1656466 0.85 GPBAR1 (0.81) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL16225956 0.84 GPBAR1 (0.65) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL20963021 0.83 GPBAR1 (0.82) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL20008824 0.82 MAPT (0.62) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
SCHEMBL20012664 0.82 MAPT (0.62) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
Lagodeoxycholate SCHEMBL23781785 0.81 GPBAR1 (0.96) GPBAR1NR1H4SLC10A2PDE3ATBXA2R
Lagodeoxycholate SCHEMBL24032585 0.81 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2PDE3ATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090232913-A1 Composition for the Control of Cholesterol Levels VANADIS BIOSCIENCE LTD. (NZ) 2009-09-17 — — US claimed
US-20090232913-A1 Composition for the Control of Cholesterol Levels VANADIS BIOSCIENCE LTD. (NZ) 2009-09-17 — — US disclosed
US-20090074895-A1 COMPOSITION AND USES THEREOF VANADIS BIOSCIENCE LTD (NZ) 2009-03-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090232913-A1 Composition for the Control of Cholesterol Levels CETP, HMGCR, CYP46A1 GPBAR1 96/4885NR1H4 12/4885SLC10A2 18/4885
US-20090074895-A1 COMPOSITION AND USES THEREOF SLC5A2, SLC5A1, SLC10A1 GPBAR1 97/4885NR1H4 9/4885SLC10A2 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback